BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharmaconomics//FDA Catalyst Calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
BEGIN:VEVENT
UID:pharmaconomics-913@pharmaconomics
DTSTAMP:20260707T040344Z
DTSTART;VALUE=DATE:20260501
DTEND;VALUE=DATE:20260502
SUMMARY:UTHR Phase 2 — Tyvaso
DESCRIPTION:Phase 2 trial results for Tyvaso in idiopathic pulmonary fibrosis are due May 1\, 2026. A clean hit validates the program\; a miss can gap the stock down hard.\n\nPrimary source: https://www.sec.gov/Archives/edgar/data/1082554/000110465926036445/tm2610558d1_ex99-1.htm\n\nTrack it: https://www.pharmaconomics.com/e/913
URL:https://www.pharmaconomics.com/e/913
TRANSP:TRANSPARENT
BEGIN:VALARM
TRIGGER:-P1D
ACTION:DISPLAY
DESCRIPTION:UTHR catalyst tomorrow
END:VALARM
END:VEVENT
END:VCALENDAR